Search results
Showing 1 to 2 of 2 results for cg144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)
This guidance has been updated and replaced by NICE guideline NG158.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making